These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 30244076

  • 1. The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report.
    Park S, Lee KM, Kim I, Mok J.
    Int J Infect Dis; 2018 Nov; 76():88-90. PubMed ID: 30244076
    [Abstract] [Full Text] [Related]

  • 2. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Oct 25; 62(RR-09):1-12. PubMed ID: 24157696
    [Abstract] [Full Text] [Related]

  • 3. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J, Hewison C, Cavalheiro AP, Skrahina A, Cajazeiro J, Nargiza P, Herboczek K, Rajabov AS, Hughes J, Ferlazzo G, Seddon JA, du Cros P.
    Emerg Infect Dis; 2017 Oct 25; 23(10):1711-3. PubMed ID: 28758889
    [Abstract] [Full Text] [Related]

  • 4. ▼Bedaquiline for multidrug-resistant tuberculosis.
    Drug Ther Bull; 2014 Nov 25; 52(11):129-32. PubMed ID: 25395481
    [Abstract] [Full Text] [Related]

  • 5. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB, Karaoui LR, Mansour H.
    Ann Pharmacother; 2014 Jan 25; 48(1):107-15. PubMed ID: 24259600
    [Abstract] [Full Text] [Related]

  • 6. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV, Estrada SJ.
    Pharmacotherapy; 2014 Nov 25; 34(11):1187-97. PubMed ID: 25203970
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B, TMC207-C209 Study Group.
    Eur Respir J; 2016 Feb 25; 47(2):564-74. PubMed ID: 26647431
    [Abstract] [Full Text] [Related]

  • 11. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
    Gao JT, Du J, Wu GH, Pei Y, Gao MQ, Martinez L, Fan L, Chen W, Xie L, Chen Y, Wang H, Jin L, Li GB, Zong PL, Xiong Y, Wu QH, Li MW, Yan XF, Miao YF, Cai QS, Li XJ, Bai DP, Geng SJ, Yang GL, Tang PJ, Zeng Y, Chen XH, Li TX, Cai C, Zhou Y, Zhuo M, Wang JY, Guan WL, Xu L, Shi JC, Shu W, Cheng LL, Teng F, Ning YJ, Xie SH, Sun YX, Zhang LJ, Liu YH.
    Infect Dis Poverty; 2021 Mar 19; 10(1):32. PubMed ID: 33736710
    [Abstract] [Full Text] [Related]

  • 12. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
    Kunkel A, Cobelens FG, Cohen T.
    PLoS Med; 2016 Oct 19; 13(10):e1002142. PubMed ID: 27727274
    [Abstract] [Full Text] [Related]

  • 13. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U, Huerga H, Khan AJ, Mitnick CD, Hewison C, Varaine F, Bastard M, Rich M, Franke MF, Atwood S, Khan PY, Seung KJ.
    BMC Infect Dis; 2019 Aug 20; 19(1):733. PubMed ID: 31429722
    [Abstract] [Full Text] [Related]

  • 14. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
    Gao M, Gao J, Xie L, Wu G, Chen W, Chen Y, Pei Y, Li G, Liu Y, Shu W, Fan L, Wu Q, Du J, Chen X, Tang P, Xiong Y, Li M, Cai Q, Jin L, Mei Z, Pang Y, Li L.
    Clin Microbiol Infect; 2021 Apr 20; 27(4):597-602. PubMed ID: 32553880
    [Abstract] [Full Text] [Related]

  • 15. Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline.
    Furin J, Diacon AH, Andries K.
    Int J Tuberc Lung Dis; 2017 Jan 01; 21(1):4-5. PubMed ID: 28157457
    [No Abstract] [Full Text] [Related]

  • 16. Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review.
    Charan J, Reljic T, Kumar A.
    Indian J Pharmacol; 2016 Jan 01; 48(2):186-91. PubMed ID: 27127322
    [Abstract] [Full Text] [Related]

  • 17. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
    Nguyen TV, Cao TB, Akkerman OW, Tiberi S, Vu DH, Alffenaar JW.
    Expert Rev Clin Pharmacol; 2016 Aug 01; 9(8):1025-37. PubMed ID: 27322153
    [Abstract] [Full Text] [Related]

  • 18. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E.
    Appl Health Econ Health Policy; 2018 Feb 01; 16(1):43-54. PubMed ID: 28980217
    [Abstract] [Full Text] [Related]

  • 19. Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults.
    Gras J.
    Drugs Today (Barc); 2013 Jun 01; 49(6):353-61. PubMed ID: 23807939
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.